Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries
Status:
Terminated
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The overall objective of LUCHAR Specific Aims 4.1 and 4.2 is to assess the additional
contribution of cardiovascular disease (CVD) risk markers to traditional biomedical risk
factors in the prediction of pre-clinical CVD. Specific Aim 4.3 will test the impact of
omega-3 fatty acid supplementation on risk markers and pre-clinical markers of CVD in
Hispanic patients.
Specific Aim 4.3: Conduct a randomized, placebo-controlled trial of the effect of omega-3
fatty acid supplementation on vascular function as measured by brachial artery reactivity
(BAR) and on circulating inflammatory markers.
Hypotheses:
1. Daily omega-3 fatty acid supplementation will improve vascular function in subjects at
high risk for CVD.
2. Daily omega-3 fatty acid supplementation will reduce inflammatory protein panel scores
in subjects at high risk for CVD.
Phase:
Phase 3
Details
Lead Sponsor:
Denver Health and Hospital Authority
Collaborators:
GlaxoSmithKline National Heart, Lung, and Blood Institute (NHLBI)